Watson to Become World’s Third Largest Generics Company with US$5.9 B Actavis Buyout
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 5 (Table of Contents)
Published: 2 May-2012
DOI: 10.3833/pdr.v2012.i5.1736 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
After much speculation, Watson Pharmaceuticals has announced that it is to acquire fellow generics company Actavis Group for €4.25 B (US$5.6 B) upfront and €250 M (US$329 M) in future Watson common stock. The purchase will create the third largest global generics company, behind Teva Pharmaceutical Industries and Novartis, with pro forma 2012 revenues of approximately US$8 B. It will also significantly enhance Watson’s global presence, particularly in established European markets and emerging markets in Central and Eastern Europe.
Copyright: © IQVIA 2018
RSS